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INTRODUCTION
According to the recent studies it has been proved that the 
solid tumors’ extracellular pH is more acidic than the normal 
tissue. However, the intracellular pH is similar to normal cells 
or even a bit more basic. To regulate the pH gradient between 
the intracellular and extracellular compartments the tumour 
cells excrete ion transport proteins, such as, H+- ATPase, Cl-/
HCO3- exhanger etc (1). Many tumours also express CAs, 
the Zn (II) dependent enzymes catalyzing the hydration of 
carbon dioxide to from bicarbonate and a proton (2-4). 
In the animal world, there are 16 isozymes of CA. These 
enzymes differ in their subcellular localization, catalytic 
activity and susceptibility to different classes of inhibitors. 
Some of them are cytosolic (CA I, CA II, CA III, CA VII 
and CA XIII), others are membrane-bound (CA IV, CA 
IX, CA XII, CA XIV and CA XV), two are mitochondrial 
(CA VA and CA VB) and one is secreted in saliva and milk 
(CA VI) (5-9). It has been reported that CA XV isoform 
is not expressed in humans or in other primates but it is 
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plentiful in rodents and other higher vertebrates (10). CAs 
play an important role in several biological processes: acid-
base balance, respiration, carbon dioxide and ion transport, 
bone resorption, ureagenesis, gluconeogenesis, lipogenesis, 
etc (11, 12). 
Among these subtypes the CA IX and XII are highly secreted 
in some tumors and mostly associated with oncogenesis (13). 
The previous studies have also indicated that the CA I and 
II levels were also higher  in several cancer types, such as 
higher cytosolic erythrocte levels in stomach, prostate, lung 
and ovary tumors; also in hematological diseases such as 
leukemia (14). Also, CA II has come to the forefront by being 
expressed in the endothelium of neovessels in some cancer 
tissues, including melanoma, esophageal, renal and lung 
cancers (15). Furthermore, CA I and II showed significant 
antiglaucoma effect. It was reported that hCA I and hCA II 
inhibitors can be used at cerebral edema, glaucoma, altitude 
sickness (16).
The aromatic/heterocyclic sulfonamide derivatives are 
broadly known as potent inhibitors of CAs (17). It has 
been known that acetazolamide (AAZ), methazolamide 
(MZA), ethoxzolamide (EZA), dorzolamide (DZA), 
brinzolamide (BRZ), topiramate (TPM), sulpiride (SLP), 
dichlorophenamide (DCP), indisulam (IND) and zonisamide 
(ZNS) are clinically used as hCA inhibitors.
In this paper, the synthesis and biological evaluation 
of a series of N-(5-methyl-1,3,4-thiadiazol-2-yl)-4-[(3-
substituted)ureido]benzenesulfonamide and N-(5-methyl-
1,3,4-thiadiazol-2-yl)-4-[(3-substituted)thioureido]
benzenesulfonamide derivatives as hCA-I and hCA-II 
inhibitors has been reported. 
MATERIAL AND METHODS
Chemistry
All the reagents were obtained commercially and used by 
further purification using standard procedures. Melting 
points were determined by Schmelzpunktbestimmer SMP 
II  apparatus. The IR spectra were recorded on a Schimadzu 
FTIR 8400 S Spectrometer. The 1H-NMR spectra were 
recorded (in DMSO-d6) with a Varian Mercury 300 MHz 
spectrometer. The chemical shift values are expressed in ppm 
(δ scale) using tetramethylsilane as an internal standard. 
The mass spectral measurements were carried out by 
Atmospheric Pressure Chemical Ionization (APCI)  method 
on LC-MS-Agilent 1100. Elemental analysis was performed 
on Leco 215 CHNS-932 analyzer. 
General procedure for the preparation of urea derivatives 
(1-9)
Sulfamethizole (0.00105 mol, 0.280 g) was solved in acetone, 
at 80 °C. Then, a solution of the corresponding isocyanate 
(0.00105mol) in dry acetone was added as two parts, per 30 
minutes. After 6 hours the reaction was finalized by TLC 
control and left overnight. The precipitate was filtered off, 
dried and purified with ethanol.
4-{[(3-Chloro-4-methylphenyl)carbamoyl]amino}-N-(5-
methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide (1)
Starting from sulfamethizole (0.280 g), 3-chloro-4-
methylphenylisocyanate (0.180 g) in dry acetone for 6 h, 
the title compound 1 was obtained. Yield: 26 %; M.p. 226-
228 °C; IR (cm-1): 3310, 3275, 3030, 2903, 1692, 1613, 1586, 
1526, 1491, 1136. 1H-NMR (300 MHz), (DMSO-d6/TMS) 
ppm: 2.25 (s, 3H, CH3), 2.52 (s, 3H, CH3), 7.52-8.60 (m, 7H, 
Ar-H), 9.62 (s, 2H, NH), 13.85 (s, 1H, -SO2NH-). Anal.calc. 
for C17H16ClN5O3S2: C, 46.63; H, 3.68; N, 15.99; S, 14.64 %. 
Found C, 47.14; H, 3.65; N, 16.27; S, 14.35 %. MS (APCI Neg 
Ion) m/z: 436.06. 
4-[(tert-Butylcarbamoyl)amino]-N-(5-methyl-1,3,4-
thiadiazol-2-yl)benzenesulfonamide (2)
Starting from sulfamethizole (0.280 g), tert-butylisocyanate 
(0.120 ml) in dry acetone for 6 h, the title compound 2 was 
obtained. Yield: 15%; M.p. 215 °C; IR (cm-1): 3364, 3129, 
3011, 2982, 2899, 2805, 1678, 1522, 1316, 1134. 1H-NMR 
(300 MHz), (DMSO-d6/TMS) ppm: 3.35 (s, 9H, (CH3)C-), 
2.51 (s, 3H, -CH3), 6.21 (s, 1H, (CH3)C-NH), 7.37 (d, 2H, 
J: 8.7 Hz, Ar-H), 7.58 (d, 2H, J: 8.7 Hz, Ar-H), 8.66 (s, 1H, 
-NH-), 13.85  (s, 1H, -SO2NH-). Anal.calc. for C14H19N5O3S2: 
C, 45.51; H, 5.18; N, 18.96; S, 17.36 %. Found C, 45.20; H, 
5.16; N, 18.91; S, 17.02 %. MS (APCI Neg Ion) m/z: 368.18.
4-[(Butylcarbamoyl)amino]-N-(5-methyl-1,3,4-thiadiazol-
2-yl)benzenesulfonamide (3)
Starting from sulfamethizole (0.280 g), butylisocyanate 
(0.121 ml) in dry acetone for 6 h, the title compound 3 was 
obtained. Yield: 70%; M.p. 259 °C; IR (cm-1): 3374, 3129, 
3021, 2955, 2895, 1680, 1641, 1557, 1526, 1492, 1402, 1323, 
1140. 1H-NMR (300 MHz), (DMSO-d6/TMS) ppm: 0.80 
(t, 3H, -CH2-CH2-CH2-CH3), 1.20-1.85 (m, 4H, -CH2-CH2-
CH2-CH3), 2.50 (s, 3H, -CH3), 2.95 (q, 2H, -NH-CH2-CH2-
CH2-CH3), 6.09 (t, 1H, -NH-CH2-CH2-CH2-CH3), 6.50-7.40 
(m, 4H, Ar-H), 8.55 (s, 1H, -NH-), 13.80 (s, 1H, -SO2NH-). 
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Anal.calc. for C14H19N5O3S2: C, 45.51; H, 5.18; N, 18.96; S, 
17.36 %. Found C,  45.86; H, 5.12; N, 18.08; S, 17.02 %. MS 
(APCI Neg Ion) m/z: 368.20.
N-(5-Methyl-1,3,4-thiadiazol-2-yl)-4-{[(4-nitrophenyl)
carbamoyl]amino}benzenesulfonamide (4)
Starting from sulfamethizole (0.280 g), 
4-nitrophenylisocyanate (0.130 ml) in dry acetone for 6 
h, the title compound 4 was obtained. Yield: 55%; M.p. 
250-252 °C; IR (cm-1): 3308, 3279, 3223, 3102, 3015, 2889, 
1690, 1593, 1562, 1530, 1505, 1435,1400, 1341, 1314, 1134. 
1H-NMR (300 MHz), (DMSO-d6/TMS) ppm: 2.49 (s, 3H, 
-CH3), 7.61-8.21 (m, 8H, Ar-H), 9.33-9.52 (s, 2H, -NH-
), 13.90 (s, 1H, -SO2NH-). Anal.calc. for C16H14N6O5S2: C, 
44.23; H, 3.25; N, 19.34; S, 14.76 %. Found C, 44.63; H, 3.32; 
N, 19.64; S, 15.00 %. MS (APCI Neg Ion) m/z : 433.10.
4-{[(2,4-Dichlorophenyl)carbamoyl]amino}-N-(5-methyl-
1,3,4-thiadiazol-2-yl)benzenesulfonamide (5)
Starting from sulfamethizole (0.280 g), 
2,4-dichlorophenylisocyanate (0.130 ml) in dry acetone for 
6 h, the title compound 5 was obtained. Yield: 60%; M.p. 
153-155 °C; IR  (cm-1): 3308, 3273, 3109, 3034, 2857, 1692, 
1584, 1526, 1495, 1470, 1404, 1325, 1153. 1H-NMR (300 
MHz), (DMSO-d6/TMS) ppm: 2.53 (s, 3H, -CH3), 7.48-8.59 
(m, 7H, Ar-H), 9.92 (s, 2H, -NH-), 13.88 (s, 1H, -SO2NH-). 
Anal.calc. for C16H13Cl2N5O3S2: C, 41.93; H, 2.86; N, 15.28; S, 
13.99 %. Found C, 41.39; H, 3.14; N, 16.05; S, 14.26 %. MS 
(APCI Neg Ion) m/z : 456.08. 
4-{[(2,6-Dichlorophenyl)carbamoyl]amino}-N-(5-methyl-
1,3,4-thiadiazol-2-yl)benzenesulfonamide (6)
Starting from sulfamethizole (0.280 g), 
2,6-dichlorophenylisocyanate (0.130 ml) in dry acetone for 
6 h, the title compound 6 was obtained. Yield: 65%; M.p. 
190-191 °C; IR   (cm-1): 3293, 3146, 3042, 2907, 1651, 1530, 
1491, 1458, 1437, 1402, 1314, 1128. 1H-NMR (300 MHz), 
(DMSO-d6/TMS) ppm: 2.49 (s, 3H, -CH3), 7.30-7.70 (m, 
7H, Ar-H), 8.34-9.40 (s, 2H, -NH-), 11.10 (s, 1H, -SO2NH-). 
Anal.calc. for C16H13Cl2N5O3S2: C, 41.93; H, 2.86;  N, 15.28; 
S, 13.99 %. Found C, 42.24; H, 2.77; N, 15.73; S, 13.85 %. MS 
(APCI Neg Ion) m/z : 456.06.
N - ( 5 - Me t hy l - 1 , 3 , 4 - t hi a d i a z o l - 2 - y l ) - 4 - { [ ( 2 , 4 , 6 -
trichlorophenyl)carbamoyl]amino}benzenesulfonamide (7)
Starting from sulfamethizole (0.280 g), 
2,4,6-trichlorophenylisocyanate (0.130 ml) in dry acetone 
for 6 h, the title compound 7 was obtained. Yield: 45%; 
M.p.    183-184 °C; IR (cm-1): 3281, 3256, 3206, 3086, 3015, 
2980, 1659, 1574, 1537, 1452, 1134. 1H-NMR  (300 MHz), 
(DMSO-d6/TMS) ppm: 2.51 (s, 3H, -CH3), 7.74 (s, 6H, Ar-H), 
8.63 (s, 2H, -NH-). Anal.calc. for C16H12Cl3N5O3S2 (492.787): 
C, 39.00; H, 2.45; N, 14.21; S, 13.01 %. Found C, 39.27; H, 
2.40; N, 14.32; S, 13.02 %. 
N - ( 5 - M e t h y l - 1 , 3 , 4 - t h i a d i a z o l - 2 - y l ) - 4 - ( { [ 4 -
(trifluoromethyl)phenyl]carbamoyl}amino)benzene-
sulfonamide (8)
Starting from sulfamethizole (0.280 g), 4-(trifluoromethyl)
phenylisocyanate (0.130 ml) in dry acetone for 6 h, the 
title compound 8 was obtained. Yield: 50%; M.p. 201-
203 °C; IR (cm-1): 3310, 3283, 3125, 3109, 3084, 3013, 
2982, 1690, 1591, 1533, 1516, 1400, 1314, 1140. 1H-NMR 
(300 MHz), (DMSO-d6/TMS) ppm: 2.49 (s, 3H, -CH3), 7.39-
7.73 (m, 8H, Ar-H), 9.20-9.22 (s, 2H, -NH-), 13.90 (s, 1H, 
-SO2NH-). Anal.calc. for C17H14F3N5O3S2: C, 44.63; H, 3.08; 
N, 15.31; S, 14.02%. Found C, 44.60; H, 3.06; N, 15.34; S, 
14.12 %. MS (APCI Neg Ion) m/z : 456.18.
N-(5-Methyl-1,3,4-thiadiazol-2-yl)-4-{[(2-phenylethyl)
carbamoyl]amino}benzenesulfonamide (9)
Starting from sulfamethizole (0.280 g), 
2-phenylethylisocyanate (0.130 ml) in dry acetone for 6 h, 
the title compound 9 was obtained. Yield: 65%; M.p. 208-209 
°C; IR (cm-1): 3362, 3096, 3011, 2888, 1670, 1589, 1526, 1441, 
1402, 1319, 1134. 1H-NMR (300 MHz), (DMSO-d6/TMS) ppm: 
2.56 (s, 3H, -CH3), 2.85-2.89 (t, 3H, -CH2-),  3.46 (t,  3H, 
-CH2NH-) 7.31-7.77 (m, 9H, Ar-H), 9.06 (s, 2H, -NH-), 13.95 
(s, 1H, -SO2NH-). Anal.calc. for C18H19N5O3S2 (417.505): C, 
51.78; H, 4.59; N, 16.77; S, 15.36%. Found C, 51.64; H, 4.48; 
N, 17.23; S, 15.16 %.
General procedure for the preparation of thiourea 
derivatives (10-14)
Sulfamethizole (0.00105 mol, 0.280 g) was solved in acetone, 
at 80 °C. Then, a solution of the corresponding isothiocyanate 
(0.00105 mol) in acetone was added as two parts, per 30 
minutes. After 6 hours the reaction was finalized by TLC 
control and left overnight. The precipitate was filtered off, 
dried and purified with ethanol.
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4-{[(4-Methylphenyl)carbamothioyl]amino}-N-(5-methyl-
1,3,4-thiadiazol-2-yl)benzenesulfonamide (10)
Starting from sulfamethizole (0.280 g), 
4-methylphenylisothiocyanate (0.157 g) in dry acetone for 
6 h, the title compound 10 was obtained. Yield: 34%; M.p. 
174-177 °C; IR (cm-1): 3325, 3275, 3123, 3011, 2861, 1586, 
1512, 1346, 1317, 1146, 1132, 1290. 1H-NMR (300 MHz), 
(DMSO-d6/TMS) ppm: 2.25 (s, 3H, CH3), 2.53 (s, 3H, -CH3), 
7.35-7.86 (m, 8H, Ar-H), 9.17 (s, 2H, -NH-), 13.90 (s, 1H, 
-SO2NH-). Anal.calc. for C17H17N5O2S3: C, 48.67; H, 4.08; N, 
16.69; S, 22.93%. Found  C, 48.36; H, 4.16; N, 16.69; S, 22.13 %. 
MS (APCI Neg Ion) m/z : 418.06.
N-(5-Methyl-1,3,4-thiadiazol-2-yl)-4-{[(4-nitrophenyl)
carbamothioyl]amino}benzenesulfonamide (11)
Starting from sulfamethizole (0.280 g), 
4-nitrophenylisothiocyanate (0.077 g) in dry acetone for 
6 h, the title compound 11 was obtained. Yield: 65%; M.p. 
181-183 °C; IR (cm-1): 3318, 3291, 3048, 2916, 2822, 1595, 
1537, 1510, 1499, 1427, 1414, 1327, 1134, 1279. 1H-NMR 
(300 MHz), (DMSO-d6/TMS) ppm: 2.53 (s, 3H, -CH3), 
7.71-8.31 (m, 9H, Ar-H), 10.59-10.63 (s, 2H, -NH-), 13.90 
(s, 1H, -SO2NH-). Anal.calc. for C16H14N6O4S3: C, 42.66; H, 
3.13; N, 18.65; S, 21.35%. Found C, 42.56; H, 3.11; N, 18.62; 
S, 21.22 %. 
4-{[(4-Bromophenyl)carbamothioyl]amino}-N-(5-methyl-
1,3,4-thiadiazol-2-yl)benzenesulfonamide (12)
Starting from sulfamethizole (0.280 g), 
4-bromophenylisothiocyanate (0.077 g) in dry acetone for 6 h, 
the title compound 12 was obtained. Yield: 60%; M.p. 170-
172 °C; IR (cm-1): 3320, 3264, 3165, 3119, 3102, 3013, 2976, 
2922, 2872, 2857, 2814, 1587, 1530, 1487, 1433, 1316, 1146, 
1292. 1H-NMR (300 MHz), (DMSO-d6/TMS) ppm:  2.49
(s ,  3H, -CH3), 7.38-7.75 (m, 8H, Ar-H), 9.93 10.32 (s, 2H, 
-NH-), 13.90 (s, 1H, -SO2NH-). Anal.calc. for C16H14BrN5O2S3: 
C, 39.67; H, 2.91; N, 14.46; S, 19.86%. Found C, 40.21; H, 
3.02; N, 14.25; S, 19.56 %. MS (APCI Neg Ion) m/z : 482.02. 
4-{[(2,6-Difluorophenyl)carbamothioyl]amino}-N-(5-
methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide (13)
Starting from sulfamethizole (0.280 g), 
2,6-difluorophenylisothiocyanate (0.077 g) in dry acetone 
for 6 h, the title compound 13 was obtained. Yield: 60%; 
M.p. 216-218 °C; IR (cm-1): 3275, 3092, 2988, 2870 2857, 
2822, 1586, 1518, 1506, 1464, 1435, 1350,1339, 1148, 1296. 
1H-NMR (300 MHz), (DMSO-d6/TMS) ppm: 2.49 (s, 3H, 
-CH3), 7.13-7.76 (m, 7H, Ar-H), 9.45-10.41(s, 2H, -NH-), 
13.90 (s, 1H, -SO2NH-). Anal.calc. for C16H13F2N5O2S3: C, 
43.88; H, 2.47; N, 15.21; S, 21.32 %. Found C, 43.53; H, 2.97; 
N, 15.86; S, 21.79 %. MS (APCI Neg Ion) m/z : 440.12.
4-{[(2,6-Dichlorophenyl)carbamothioyl]amino}-N-(5-
methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide (14)
Starting from sulfamethizole (0.280 g), 
2,6-chlorophenylisothiocyanate (0.077 g) in dry acetone for 
6 h, the title compound 14 was obtained. Yield: 55%; M.p. 
221-222 °C; IR (cm-1): 3335, 3237, 3032, 2893, 1516, 1499, 
1433, 1350, 1150, 1292. 1H-NMR (300 MHz), (DMSO-d6/
TMS) ppm: 2.49 (s, 3H, -CH3), 7.33-7.77 (m, 7H, Ar-H), 
9.69-10.33 (s, 2H, -NH-), 13.90 (s, 1H, -SO2NH-). Anal.calc. 
for C16H13Cl2N5O2S3: C, 40.51; H, 2.76; N, 14.76; S, 20.28%. 
Found C, 40.86; H, 2.82; N, 15.17; S, 20.26. MS (APCI Neg 
Ion) m/z : 472.05.
Biological activitiy
Purification of carbonic anhydrase from human 
erythrocytes
Erythrocytes were purified from human blood obtained from 
Blood Center of Research Hospital at Ataturk University. 
Carbonic anhydrases isoenzymes (hCA-I and hCA-II) from 
human erythrocytes were purified by means of affinity column 
having a structure of Sepharose 4B-L-tyrosine-sulfonyamide 
(18) and the study was carried out with these enzymes. The 
eluates were plotted by doing protein determination at 280 
nm and CO2-hydratase activity (19). 
Determination of carbonic anhydrase activity and effect of 
compounds 1-14 on isoenzymes
Carbonic anhydrase activity and effect of the synthesized 
compounds were assayed by hydration of CO2. Carbonic 
anhydrase activity was determined using the Wilbur–
Anderson Method which was modified by Rickli and Sly 
(19, 20).  CO2-Hydratase activity as enzyme unit (EU) was 
calculated by the equation (to-tc/tc) where to and tc are the 
times for pH change of the non-enzymatic (buffer) and the 
enzymatic reaction, respectively.
Determination of IC50 values
It was studied with compounds 1-14 to calculate values of 
IC50 of hCA-I and hCA-II enzymes on the hydratase activity 
at different concentrations while maintaining constant 
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the substrate concentration. Activities of enzymes in the 
medium without inhibitors were used as 100% activity. The 
activity % values of enzymes were calculated by measuring 
hydratase activity in the presence of different concentrations 
of inhibitors. The IC50 value was calculated by utilizing graphs 
of % activity-[I] for each inhibitor (21, 22).
RESULTS AND DISCUSSION
The synthetic route to the target compounds is outlined 
in Scheme 1. The urea and thiourea derivatives were 
prepared by reacting equimolar isocyanates or thiocyanates 
and sulfamethiazole. Physicochemical and spectroscopic 
characterization of the urea and thiourea derivatives have 
been previously described. The structures of the compounds 
(1-14) were confirmed by IR, 1H-NMR, MS and elemental 
analysis. IR spectra of the compounds (1-14) afforded urea/
thiourea and sulfonamide N-H streching 3374-3102cm-1 and 
C=O streching 1692-1651cm-1 bands and aromatic rings’ 
C-H streching 3096-3011cm-1 bands. The NH protons of 
urea groups resonated as a singlet or two different singlet 
peak because of E/Z isomer at  6.09-10.63 ppm. NH protons 
of sulfonamide groups appeared as a singlet at 11.10-13.95 
ppm. The protons belonging to the aromatic ring and the 
other aliphatic groups were observed with the expected 
chemical shift and integral values. Mass spectra (APCI) of 
compounds showed a (M-1) peak, in line with their molecular 
formula. Also, the elemental analysis of compounds were in 
agreement with the proposed structures of the compounds.
Scheme 1. The synthesis route of the compounds (1-14)
Table 1. Results obtained from regression analysis graphs for hCA-I and hCA-II presence of compounds.
Compound R/Ar hCA-I Inhibition* (IC50) hCA-II Inhibition* (IC50) hCA-I / hCA-II
1 3-Cl-4-CH3-C6H3- 2.19 - -
2 (CH3)3-C- 10.25 1.65 6.21
3 CH3-(CH2)3- 6.08 1.696 3.58
4 4-NO2-C6H4- 2.37 6.71 0.35
5 2,4-diCl-C6H3- 3.48 11.17 0.31
6 2,6-diCl-C6H3- 4.99 9.34 0.53
7 2,4,6-triCl-C6H2- 15.65 13.36 1.17
8 4-CF3-C6H4- 6.44 17.95 0.36
9 C6H5-(CH2)2- ND ND ND
10 4-CH3-C6H4- 0.144 0.109 1.32
11 4-NO2-C6H4- 3.14 5.60 0.56
12 4-Br-C6H4- 2.42 1.52 1.59
13 2,6-diF-C6H3- 8.78 2.33 3.77
14 2,6-diCl-C6H3- 6.68 8.37 0.80
Sulfamethizole - 0.304 0.194 1.57
Acetazolamide (AAZ) - 6.2** 7.4** 0.84**
*They were determined as nM, ** They were determined as µM, ND: Not determined.
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All of the compounds had inhibitory activity on hCA-I 
and except 1 on hCA-II against the reference compound 
acetazolamide (AAZ) (Table 1). The ureas which have alkyl 
substitutions (2, 3) and halogen substituted 7; thioureas 
which have alkyl substitution (10) and halogen substitutions 
on their aromatic ring (12, 13) were more significant on 
hCA-II than hCA-I, whereas the inhibitory effects of six 
derivatives (4, 5, 6, 8, 11, 14) were more selective on hCA-I 
than hCA-II. 
The inhibitory effects of the compounds 3, 8, 14 and 1, 4, 
12 on hCA-I were fairly close with the IC50 values between 
6.08-6.68 and 2.19-2.42 nM, respectively. Although 4, 5, 6, 8, 
11, 14 had lower hCA-I/hCA-II ratio than the hCA-I/hCA-II 
ratio of AAZ and the ratio of 14 was quite close to the hCA-I/
hCA-II ratio of AAZ. 
CONCLUSIONS
Here, we synthesized urea and thiourea derivatives and 
evaluated their ability to inhibit carbonic anhydrase isozymes 
(hCA-I and hCA-II) against the reference compound AAZ. 
The compounds 1-3 and 11-14 had remarkable inhibitory 
activity on hCA-I and 2, 3, 10 and all 11-14 series had 
remarkable inhibitory activity on hCA-II. The compound 
2 was the most powerful compound on hCA-II, with the 
hCA-I/hCA-II ratio value 6.21. On the other hand 5 and 
8 showed the most inhibitory activity on hCA-I with the 
range of 0.31 and 0.36 hCA-I/hCA-II ratio, respectively. 
These synthesized two compounds (5 and 8) may be served 
as model compounds to design new hCA-I and hCA-II 
inhibitory agents for further studies. 
Karbonik anhidraz I ve II inhibitörü olan bazı N-(5-metil-
1,3,4-tiyadiazol-2-il)-4-[(3-sübstitüe)üreido/tiyoüreido]
benzensülfonamitler
ÖZ
Bu çalışmada N-(5-metil-1,3,4-tiyadiazol-2-il)-4-[(3-sübstitüe)
üreido]benzensülfonamit ve N-(5-metil-1,3,4-tiyadiazol-2-
il)-4-[(3-sübstitüe)tiyoüreido]benzensülfonamit türevleri 
4-amino-N-(5-metil-1,3,4-tiyadiazol-2-il)benzensülfonamitten 
(sülfametizol) hareketle sentez edildi. Bütün yeni bileşiklerin 
yapıları elemental analiz ve çeşitli spektroskopik yöntemler 
(FTIR, 1H-NMR ve MS) yardımıyla aydınlatıldı. Bu yeni 
sülfonamit türevlerinin, özellikle insan karbonik anhidraz 
I ve II olmak üzere, karbonik anhidraz inhibitor etkileri 
incelendi. Bileşiklerin klinikte kullanılan asetazolamide kıyasla 
insan sitozolik CA I (IC50 değerleri 0.144-15.65 nM) ve CA II 
(IC50 değerleri 0.109-17.95 nM) inhibisyon değerleri ile daha 
yüksek aktivite gösterdikleri tespit edildi.
Anahtar kelimeler: Karbonik anhidraz inhibitörleri, sülfonamit, 
sülfametizol, üre ve tiyoüre.
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